Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface.

Zhang X, Pickin KA, Bose R, Jura N, Cole PA, Kuriyan J.

Nature. 2007 Nov 29;450(7170):741-4.

2.

Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6.

Park E, Kim N, Ficarro SB, Zhang Y, Lee BI, Cho A, Kim K, Park AKJ, Park WY, Murray B, Meyerson M, Beroukhim R, Marto JA, Cho J, Eck MJ.

Nat Struct Mol Biol. 2015 Sep;22(9):703-711. doi: 10.1038/nsmb.3074. Epub 2015 Aug 17.

3.

Truncation, modification, and optimization of MIG6(segment 2) peptide to target lung cancer-related EGFR.

Yu XD, Yang R, Leng CJ.

Comput Biol Chem. 2016 Apr;61:251-7. doi: 10.1016/j.compbiolchem.2016.02.015. Epub 2016 Mar 9.

PMID:
26967626
4.

The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations.

Endo H, Okami J, Okuyama H, Nishizawa Y, Imamura F, Inoue M.

Oncogene. 2017 May 18;36(20):2824-2834. doi: 10.1038/onc.2016.431. Epub 2016 Nov 28.

PMID:
27893711
5.

Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.

Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J.

Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21608-13. doi: 10.1073/pnas.0912101106. Epub 2009 Dec 9.

6.

The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors.

Izumchenko E, Chang X, Michailidi C, Kagohara L, Ravi R, Paz K, Brait M, Hoque MO, Ling S, Bedi A, Sidransky D.

Cancer Res. 2014 Jul 15;74(14):3995-4005. doi: 10.1158/0008-5472.CAN-14-0110. Epub 2014 May 15. Erratum in: Cancer Res. 2014 Sep 1;74(17):4950-1.

7.

Type I γ Phosphatidylinositol Phosphate 5-Kinase i5 Controls the Ubiquitination and Degradation of the Tumor Suppressor Mitogen-inducible Gene 6.

Sun M, Cai J, Anderson RA, Sun Y.

J Biol Chem. 2016 Oct 7;291(41):21461-21473. Epub 2016 Aug 24.

PMID:
27557663
8.

Understanding the molecular basis of EGFR kinase domain/MIG-6 peptide recognition complex using computational analyses.

Moonrin N, Songtawee N, Rattanabunyong S, Chunsrivirot S, Mokmak W, Tongsima S, Choowongkomon K.

BMC Bioinformatics. 2015 Mar 27;16:103. doi: 10.1186/s12859-015-0528-x.

9.

Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.

Maity TK, Venugopalan A, Linnoila I, Cultraro CM, Giannakou A, Nemati R, Zhang X, Webster JD, Ritt D, Ghosal S, Hoschuetzky H, Simpson RM, Biswas R, Politi K, Morrison DK, Varmus HE, Guha U.

Cancer Discov. 2015 May;5(5):534-49. doi: 10.1158/2159-8290.CD-14-0750. Epub 2015 Mar 3.

10.

Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation.

Ferby I, Reschke M, Kudlacek O, Knyazev P, Pantè G, Amann K, Sommergruber W, Kraut N, Ullrich A, Fässler R, Klein R.

Nat Med. 2006 May;12(5):568-73. Epub 2006 Apr 30. Erratum in: Nat Med. 2006 Jul;12(7):862.

PMID:
16648858
11.

Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.

Monsey J, Shen W, Schlesinger P, Bose R.

J Biol Chem. 2010 Mar 5;285(10):7035-44. doi: 10.1074/jbc.M109.096032. Epub 2009 Dec 18.

12.

Tyrosine phosphorylation of mig6 reduces its inhibition of the epidermal growth factor receptor.

Wang Z, Raines LL, Hooy RM, Roberson H, Leahy DJ, Cole PA.

ACS Chem Biol. 2013 Nov 15;8(11):2372-6. doi: 10.1021/cb4005707. Epub 2013 Sep 6.

13.

The juxtamembrane region of the EGF receptor functions as an activation domain.

Red Brewer M, Choi SH, Alvarado D, Moravcevic K, Pozzi A, Lemmon MA, Carpenter G.

Mol Cell. 2009 Jun 26;34(6):641-51. doi: 10.1016/j.molcel.2009.04.034.

14.

Mechanism of activation and inhibition of the HER4/ErbB4 kinase.

Qiu C, Tarrant MK, Choi SH, Sathyamurthy A, Bose R, Banjade S, Pal A, Bornmann WG, Lemmon MA, Cole PA, Leahy DJ.

Structure. 2008 Mar;16(3):460-7. doi: 10.1016/j.str.2007.12.016.

15.

The ErbB/HER family of protein-tyrosine kinases and cancer.

Roskoski R Jr.

Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20. Review.

PMID:
24269963
16.

Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor.

Lu C, Mi LZ, Schürpf T, Walz T, Springer TA.

J Biol Chem. 2012 Nov 2;287(45):38244-53. doi: 10.1074/jbc.M112.414391. Epub 2012 Sep 17.

17.
18.

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.

Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J.

Cell. 2006 Jun 16;125(6):1137-49.

19.

Mechanistic insights into the activation of oncogenic forms of EGF receptor.

Wang Z, Longo PA, Tarrant MK, Kim K, Head S, Leahy DJ, Cole PA.

Nat Struct Mol Biol. 2011 Nov 20;18(12):1388-93. doi: 10.1038/nsmb.2168.

20.

Mutation of epidermal growth factor receptor is associated with MIG6 expression.

Nagashima T, Ushikoshi-Nakayama R, Suenaga A, Ide K, Yumoto N, Naruo Y, Takahashi K, Saeki Y, Taiji M, Tanaka H, Tsai SF, Hatakeyama M.

FEBS J. 2009 Sep;276(18):5239-51. doi: 10.1111/j.1742-4658.2009.07220.x. Epub 2009 Aug 10.

Supplemental Content

Support Center